<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03964727</url>
  </required_header>
  <id_info>
    <org_study_id>Immu-132-11</org_study_id>
    <nct_id>NCT03964727</nct_id>
  </id_info>
  <brief_title>A Study of Sacituzumab Govitecan in Metastatic Solid Tumors (TROPICS-03)</brief_title>
  <official_title>A Phase 2 Open Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects With Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immunomedics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Immunomedics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2 Open Label Study of Sacituzumab Govitecan (IMMU0132) in Subjects With Metastatic
      Solid Tumors
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-cohort, open-label, Phase 2 study designed to assess the clinical activity of
      sacituzumab govitecan in adult subjects with metastatic solid tumors with elevated Trop-2
      expression.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    The study has been halted temporarily to mitigate the impact of the COVID-19 pandemic
  </why_stopped>
  <start_date type="Actual">August 6, 2019</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
    <description>Assess the objective response rate (ORR) of sacituzumab govitecan in subjects with metastatic solid tumors enriched for Trop-2 expression by investigator assessment according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR) according to RECIST 1.1 by BICR assessment</measure>
    <time_frame>every 6 weeks from Cyle1 Day 1 for an average of 6 months, each cycle is 21 days</time_frame>
    <description>Overall Response Rate (ORR) , according to RECIST 1.1 by BICR assement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the Safety Pharmacokinetics of hRS7-IgG &amp; hRS&amp;-SN38</measure>
    <time_frame>through treatment completion, an average of 6 months</time_frame>
    <description>Area under the plasma/serum/blood drug concentration-time curve (AUC) from time zero to the time of the last quantifiable concentration of hRS7-IgG &amp; hRS7-SN38</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the Plasma Concentration of hRS7-IgG &amp; hRS&amp;-SN38</measure>
    <time_frame>through treatment completion, an average of 6 months</time_frame>
    <description>Maximum Plasma Concentration (Cmax) of hRS7-IgG &amp; hRS7-SN38 from time zero to the time of the last quantifiable concentration of hRS7-IgG &amp; hRS7-SN38</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the Time of Peak Concentration of hRS7-IgG &amp; hRS&amp;-SN38</measure>
    <time_frame>through treatment completion, an average of 6 months</time_frame>
    <description>Time to Peak Concentration (Tmax) of hRS7-IgG &amp; hRS7-SN38 from time zero to the time of the last quantifiable concentration of hRS7-IgG &amp; hRS7-SN38</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the AUCinf of hRS7-IgG &amp; hRS&amp;-SN38</measure>
    <time_frame>through treatment completion, an average of 6 months</time_frame>
    <description>Area under the plasma concentration versus time curve from zero to infinity of hRS7-IgG &amp; hRS7-SN38</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the CL/f of hRS7-IgG &amp; hRS&amp;-SN38</measure>
    <time_frame>through treatment completion, an average of 6 months</time_frame>
    <description>Clearance/Bioavailability of hRS7-IgG &amp; hRS7-SN38</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the t1/2 of hRS7-IgG &amp; hRS&amp;-SN38</measure>
    <time_frame>through treatment completion, an average of 6 months</time_frame>
    <description>Terminal half life of hRS7-IgG &amp; hRS7-SN38</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity by ADA</measure>
    <time_frame>through treatment completion, an average of 6 months</time_frame>
    <description>Assess the Immunogenicity of Sacituzumab-Govitecan by Anti-Drug Assay (ADA)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Metastatic Non-Small Cell Lung Carcinoma</condition>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <condition>Endometrial Cancer</condition>
  <arm_group>
    <arm_group_label>IMMU-132</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMMU-132/Sacituzumab govitecan will be administered at 10 mg/kg as an intravenous infusion on days 1 and 8 of a 21-day cycle until disease progression (PD), toxicity or withdrawal of consent.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IMMU-132</intervention_name>
    <description>Sacituzumab govitecan will be administered at 10 mg/kg as an intravenous infusion on days 1 and 8 of a 21-day cycle until disease progression (PD), toxicity or withdrawal of consent.</description>
    <arm_group_label>IMMU-132</arm_group_label>
    <other_name>sacituzumab govitecan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female or male subjects, at least 18 years of age, able to understand and give written
             informed consent.

          -  Subjects with the following histologically documented metastatic (M1, Stage IV) or
             locally advanced solid tumors. NSCLC (adenocarcinoma or SCC), that has progressed
             after one line of platinum-based chemotherapy and PD-L1 or PD-1 directed therapy;
             recurrence/ relapse or lack of response within 6 months of completion of chemotherapy
             for locally advanced disease, that line of therapy may be counted for eligibility.
             Relapsed unresectable endometrial cancer that has progressed after prior
             platinum-based chemotherapy or is refractory to platinum-based chemotherapy.

          -  Eastern Cooperative Oncology Group (ECOG) Performance status score of 0 or 1 (see
             Appendix 1)

          -  Adequate hematologic counts without transfusional or growth factor support within 2
             weeks of study drug initiation

          -  Adequate hepatic function

          -  Subject must have at least a 3-month life expectancy.

          -  Have measurable disease by Computed Tomography (CT) or Magnetic Resonance Imaging
             (MRI) as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria (see
             Appendix 4). Tumor lesions situated in a previously irradiated area may be utilized if
             they are considered measurable and progression has been demonstrated in such lesions.

        Exclusion Criteria:

          -  Hepatitis B/C

          -  Has had a prior anti-cancer biologic agent within 4 weeks prior to study Day 1 or have
             had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2
             weeks prior to study Day 1.

          -  Have not recovered (i.e., ≤ Grade 1) from adverse events due to a previously
             administered agent

          -  Have previously received topoisomerase I inhibitors

          -  Have an active second malignancy

          -  Have known active central nervous system (CNS) metastases and/or carcinomatous
             meningitis. Subjects with previously treated brain metastases may participate provided
             they have stable CNS disease for at least 4 weeks prior to the first dose of study
             drug and all neurologic symptoms have returned to baseline, have no evidence of new or
             enlarging brain metastases and are taking ≤20 mg/day of prednisone or its equivalent.
             All subjects with carcinomatous meningitis are excluded regardless of clinical
             stability
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cabilia Pichardo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Immunomedics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Oncology</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital Anschutz Cancer Pavilion</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Cancer Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Rogel Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Mississippi Medical Centers</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>33801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine in Saint Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada- Henderson</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology - Albany Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Willamette Valley Cancer Institute and Research Center - Eugene</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Goldenberg DM, Stein R, Sharkey RM. The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. Oncotarget. 2018 Jun 22;9(48):28989-29006. doi: 10.18632/oncotarget.25615. eCollection 2018 Jun 22. Review.</citation>
    <PMID>29989029</PMID>
  </reference>
  <reference>
    <citation>Gray JE, Heist RS, Starodub AN, Camidge DR, Kio EA, Masters GA, Purcell WT, Guarino MJ, Misleh J, Schneider CJ, Schneider BJ, Ocean A, Johnson T, Gandhi L, Kalinsky K, Scheff R, Messersmith WA, Govindan SV, Maliakal PP, Mudenda B, Wegener WA, Sharkey RM, Goldenberg DM. Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan. Clin Cancer Res. 2017 Oct 1;23(19):5711-5719. doi: 10.1158/1078-0432.CCR-17-0933. Epub 2017 Jul 5.</citation>
    <PMID>28679770</PMID>
  </reference>
  <reference>
    <citation>Ocean AJ, Starodub AN, Bardia A, Vahdat LT, Isakoff SJ, Guarino M, Messersmith WA, Picozzi VJ, Mayer IA, Wegener WA, Maliakal P, Govindan SV, Sharkey RM, Goldenberg DM. Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics. Cancer. 2017 Oct 1;123(19):3843-3854. doi: 10.1002/cncr.30789. Epub 2017 May 30.</citation>
    <PMID>28558150</PMID>
  </reference>
  <reference>
    <citation>Heist RS, Guarino MJ, Masters G, Purcell WT, Starodub AN, Horn L, Scheff RJ, Bardia A, Messersmith WA, Berlin J, Ocean AJ, Govindan SV, Maliakal P, Mudenda B, Wegener WA, Sharkey RM, Goldenberg DM, Camidge DR. Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan. J Clin Oncol. 2017 Aug 20;35(24):2790-2797. doi: 10.1200/JCO.2016.72.1894. Epub 2017 May 26.</citation>
    <PMID>28548889</PMID>
  </reference>
  <reference>
    <citation>Bourauel C, Drescher D, Nolte LP. [The computer-aided development of orthodontic treatment elements made from NiTi memory alloys exemplified by a pseudoelastic retraction spring]. Fortschr Kieferorthop. 1993 Feb;54(1):45-56. German. Erratum in: Fortschr Kieferorthop 1993 Apr;54(2):9.</citation>
    <PMID>8503956</PMID>
  </reference>
  <reference>
    <citation>Bardia A, Mayer IA, Diamond JR, Moroose RL, Isakoff SJ, Starodub AN, Shah NC, O'Shaughnessy J, Kalinsky K, Guarino M, Abramson V, Juric D, Tolaney SM, Berlin J, Messersmith WA, Ocean AJ, Wegener WA, Maliakal P, Sharkey RM, Govindan SV, Goldenberg DM, Vahdat LT. Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. J Clin Oncol. 2017 Jul 1;35(19):2141-2148. doi: 10.1200/JCO.2016.70.8297. Epub 2017 Mar 14.</citation>
    <PMID>28291390</PMID>
  </reference>
  <reference>
    <citation>Cardillo TM, Sharkey RM, Rossi DL, Arrojo R, Mostafa AA, Goldenberg DM. Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1/2-wild-type Triple-Negative Breast Cancer. Clin Cancer Res. 2017 Jul 1;23(13):3405-3415. doi: 10.1158/1078-0432.CCR-16-2401. Epub 2017 Jan 9.</citation>
    <PMID>28069724</PMID>
  </reference>
  <reference>
    <citation>Faltas B, Goldenberg DM, Ocean AJ, Govindan SV, Wilhelm F, Sharkey RM, Hajdenberg J, Hodes G, Nanus DM, Tagawa ST. Sacituzumab Govitecan, a Novel Antibody--Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma. Clin Genitourin Cancer. 2016 Feb;14(1):e75-9. doi: 10.1016/j.clgc.2015.10.002. Epub 2015 Oct 19.</citation>
    <PMID>26541586</PMID>
  </reference>
  <reference>
    <citation>Sharkey RM, McBride WJ, Cardillo TM, Govindan SV, Wang Y, Rossi EA, Chang CH, Goldenberg DM. Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan). Clin Cancer Res. 2015 Nov 15;21(22):5131-8. doi: 10.1158/1078-0432.CCR-15-0670. Epub 2015 Jun 23.</citation>
    <PMID>26106073</PMID>
  </reference>
  <reference>
    <citation>Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget. 2015 Sep 8;6(26):22496-512. Erratum in: Oncotarget. 2020 Mar 10;11(10):942.</citation>
    <PMID>26101915</PMID>
  </reference>
  <reference>
    <citation>Starodub AN, Ocean AJ, Shah MA, Guarino MJ, Picozzi VJ Jr, Vahdat LT, Thomas SS, Govindan SV, Maliakal PP, Wegener WA, Hamburger SA, Sharkey RM, Goldenberg DM. First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors. Clin Cancer Res. 2015 Sep 1;21(17):3870-8. doi: 10.1158/1078-0432.CCR-14-3321. Epub 2015 May 5.</citation>
    <PMID>25944802</PMID>
  </reference>
  <reference>
    <citation>Cardillo TM, Govindan SV, Sharkey RM, Trisal P, Arrojo R, Liu D, Rossi EA, Chang CH, Goldenberg DM. Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers. Bioconjug Chem. 2015 May 20;26(5):919-31. doi: 10.1021/acs.bioconjchem.5b00223. Epub 2015 May 8.</citation>
    <PMID>25915780</PMID>
  </reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>April 29, 2019</study_first_submitted>
  <study_first_submitted_qc>May 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2019</study_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

